Results 101 to 110 of about 35,844 (248)

Effect of metformin on inflammation and bone damage in a rat model of medication‐related osteonecrosis of the jaw

European Journal of Oral Sciences, Volume 134, Issue 1, February 2026.
Abstract This study investigated how chronic metformin administration modulates the cellular profile and inflammatory markers in a zoledronic acid‐based rat model of medication‐related osteonecrosis of the jaw (MRONJ). Male Wistar rats were allocated to different treatments: (i) naïve, (ii) MRONJ (zoledronic acid, 0.2 mg/kg, i.v.
Liviane Maria Alves Rabelo, Mariana Vasconcelos Guimarães, Aurilene Gomes Cajado, José Vitor Mota Lemos, Felipe Domingos de Sousa, Nylane Maria Nunes Alencar, Vilma de Lima, Paulo Goberlânio de Barros Silva, Ana Paula Negreiros Nunes Alves, Deysi Viviana Tenazoa Wong, Roberto César Pereira Lima‐Júnior   +10 more
wiley   +1 more source

Bisphosphonate- and disumab-related gingival disorders: case analysis from the U.S. Food and Drug Administration Adverse Event Reporting System

Frontiers in Endocrinology
Prior research has indicated that bisphosphonates (BPs) can improve periodontal disease because of their anti-osteoporosis properties. In vitro studies have shown that BPs induce cytotoxicity, inhibit wound healing, and thus affect periodontal disease ...
Lei Wang, Wei Zhang, Cheng-long Zhao, Zhong-hua Fu   +3 more
doaj   +1 more source

Integrating Transcriptomics and Gut Microbiota Analysis Reveals the Anti‐Osteoporotic Mechanisms of Wine and Oil Co‐Processed Epimedium

The FASEB Journal, Volume 40, Issue 2, 31 January 2026.
Firstly, we determined the content of the components in the co‐products of Epimedium wine and oil. Secondly, the clinical indications of the co‐products of Epimedium wine and oil were determined by in vitro cell experiments. Finally, the in vivo animal model was used for experimental verification.
Jinling Liang, Shichang Li, Yulin Dai, Zifeng Pi, Jia Liu, Pan Li, Weixia Sun, Tao Jiang, Tianyang Xu, Peng Yu   +9 more
wiley   +1 more source

Severe Hypocalcemia and Hypomagnesemia with Denosumab in Advanced Chronic Kidney Disease: Case Report and Literature Review

Case Reports in Oncological Medicine, 2018
Background. Denosumab has become the preferred agent over zolendronic acid to help prevent skeletal-related events in patients with metastatic bone disease and multiple myeloma because it is approved for use in those with kidney dysfunction.
Christina F. Marlow, Shailendra Sharma, Faizan Babar, Jianqing Lin   +3 more
doaj   +1 more source

Cancer Treatment and Bone Health [PDF]

, 2018
Considerable advances in oncology over recent decades have led to improved survival, while raising concerns about long-term consequences of anticancer treatments.
A Falahati-Nini, A Garg, A Lipton, A Llombart, A Morishima, A Tomkinson, AM Brufsky, AR Hong, B Buehring, BF Boyce, BL Clarke, BL Clarke, C Christensen, C Magno, C Poznak Van, C Shapiro, C Wilson, Catherine Handforth, CH Kasperk, CJ Stava, D Goldray, D Vanderschueren, DA Cameron, DA Galvão, DL Hershman, DM Huber, DS Perrien, Early Breast Cancer Trialists, EP Smith, F Mazzuca, FA Trémollieres, GK Ellis, HG Bone, HW Daniell, I Fogelman, I Sestak, J Morote, J Pfeilschifter, J Planas, Janet Brown, JD Wilson, JE Lester, JE Lester, JF Forbes, JL Mohler, JM Bruder, KB Emerton, KM Nicks, L Bošković, L Vehmanen, LC Hofbauer, LC Hofbauer, LH Klotz, LP Fried, M Bauer, M Datta, M Gnant, M Gnant, M Kalder, M Kalder, M Rabaglio, MD Michaelson, MG Oefelein, MM Agarwal, MR Smith, MR Smith, MR Smith, MR Smith, MR Smith, MR Smith, N Majithia, N Napoli, ND James, ND Wagner-Johnston, P Hadji, P Hadji, P Hadji, P Hadji, P Rodrigues, PD Miller, PE Goss, PE Goss, PL Nguyen, R Choo, R Coleman, R Coleman, R Eastell, R Eastell, R Soleimani, RA Adler, RE Coleman, RJ Segal, Robert Coleman, S Dhesy-Thind, S D’Oronzo, SL Greenspan, Stella D’Oronzo, SY Ying, T Kameda, T Liu, T Rana, T Saarto, TA Guise, TH Diamond, TJ Powles, V Carnevale, V Subbiah, VB Shahinian, W Vale, WJ Boyle   +109 more
core   +2 more sources

The Effects of Bone‐Remodeling Therapy on Survival, Pain, and Skeletal Related Events in the Setting of Renal Cell Carcinoma With Bone Metastases: A Multicenter Investigation From a Large Global Health Research Network (TriNetX)

Cancer Medicine, Volume 15, Issue 1, January 2026.
In this retrospective population study containing 139,859 patients, subjects receiving RANK‐ligand inhibitors had improved survival and decreased rates of skeletal‐related events relative to the overall cohort of patients with metastatic bone lesions.
Brian H. Im, Kevin K. Zarrabi, Aaron R. Hochberg, Mihir S. Shah, James R. Mark, Joseph K. Izes, Patrick T. Gomella, Costas D. Lallas, Leonard G. Gomella, Adam R. Metwalli   +9 more
wiley   +1 more source

Denosumab treatment in the management of patients with advanced prostate cancer: clinical evidence and experience

Therapeutic Advances in Urology, 2017
Osteoprotective therapies have become an essential component in the management of advanced prostate cancer (PC) patients as bone metastases (BMs) have a major impact on morbidity and mortality.
Miriam Hegemann, Jens Bedke, Arnulf Stenzl, Tilman Todenhöfer   +3 more
doaj   +1 more source

Racial and Ethnic Disparities in Pharmacologic and Non‐Pharmacologic Pain Management Among Older Cancer Survivors

Cancer Medicine, Volume 15, Issue 1, January 2026.
ABSTRACT Introduction Pain is common among cancer survivors and often managed with medication; however, racial‐ethnic disparities persist in pain treatment. Given inadequate data on pharmacologic and non‐pharmacologic pain management among minoritized cancer survivors, we investigated these patterns using the SEER‐Medicare claims linked database ...
Oindrila Bhattacharyya, Mohamed I. Elsaid, Brittany E. Punches, Andy Ni, Ashley S. Felix, Macarius M. Donneyong   +5 more
wiley   +1 more source

What are we paying for? A cost-effectiveness analysis of patented denosumab and generic alendronate for postmenopausal osteoporotic women in Australia [PDF]

, 2016
Jonathan Karnon, Ainul Shakirah Shafie, Nneka Orji, Sofoora Kawsar Usman   +3 more
openalex   +1 more source

Denosumab-induced severe hypocalcemia in a patient with Crohn's disease [PDF]

, 2014
Osteoporosis occurs with increased prevalence in individuals with inflammatory bowel disease (IBD), and as such, these patients are at risk for osteoporosis-related fractures.
Katta, Natraj, Mulyala, Rajasekhar, Spiegel, Michelle, Tidwell, Tonya   +3 more
core